Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Six-month randomized comparison of SAR341402 vs NovoLog/NovoRapid in adults with diabetes using insulin glargine
2017-000091-28Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin aspart in diabetes mellitus type 1 (T1D) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in HbA1c from baseline to Week 26. Started Jun 2017; status: completed.
02
Drugs
insulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-000091-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000091-28.